Pubblicazioni

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.

2020 - MULTIPLE SCLEROSIS
Fox, E; Lovett-Racke, Ae; Gormley, M; Liu, Y; Petracca, M; Cocozza, S; Shubin, R; Wray, S; Weiss, Ms; Bosco, Ja; Power, Sa; Mok, K; Inglese, M.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma